Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850488 | 0.99 | GAA (0.55) | GAASIGMAR1L3MBTL1TDP1SRC | |
| SCHEMBL29123957 | 0.84 | PKM (0.66) | GAAL3MBTL1TDP1POLBPKM | |
| SCHEMBL30735634 | 0.82 | CYP2C19 (0.68) | TDP1MAPK1CYP2C19KMT2A | |
| SCHEMBL2854997 | 0.82 | SIGMAR1 (0.59) | GAASIGMAR1L3MBTL1SRCPARP1 | |
| SCHEMBL29123951 | 0.82 | CYP2C19 (0.68) | TDP1MAPK1CYP2C19KMT2A | |
| SCHEMBL2850490 | 0.81 | L3MBTL1 (0.58) | GAASIGMAR1L3MBTL1SRCPARP1 | |
| SCHEMBL4617661 | 0.80 | SFRP1 (0.61) | GAASIGMAR1L3MBTL1PARP1SMN1; SMN2 | |
| SCHEMBL29123974 | 0.79 | TDP1 (0.56) | SIGMAR1TDP1MAPK1CYP2C19KMT2A | |
| SCHEMBL5034887 | 0.79 | CYP2C19 (0.76) | GAATDP1MAPK1PKMCYP2C19 | |
| SCHEMBL4196782 | 0.79 | SIGMAR1 (0.73) | GAASIGMAR1L3MBTL1PARP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | GAA 4722/4885SIGMAR1 694/4885L3MBTL1 4714/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | GAA 4722/4885SIGMAR1 694/4885L3MBTL1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.